CompletedNot Applicable

Evaluation of Low-Level Light Therapy on Meibomian Glands Study

United States30 participantsStarted 2023-06-07

Plain-language summary

The goal of this clinical trial is to examine the effect of low-level light therapy (LLLT) on meibomian gland dysfunction and dry eye disease. The main questions it aims to answer are: 1. Does low-level light therapy reduce levels of pro-inflammatory proteins in meibum 2. Does low-level light therapy increase the ratio of non-polar lipids to polar lipids in meibum Participants will receive 3 15-minute sessions of low-level light therapy. Meibum will be collected before the first treatment and after the final treatment.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age 18 years or older at enrollment * Individuals with mild to moderate meibomian gland dysfunction based on clinical signs, e.g., meibum quality score of 1-3, meibography score of 1, 2, or 3 on the Pult Meiboscale, non-invasive 1st tear break up time of 10 seconds or less, or an Ocular Surface Disease Index (OSDI) score of 13 to 32 points Exclusion Criteria: * History of systemic disease associated with aqueous-deficient dry eye disease (e.g., Sjogren's syndrome) * History of corneal surgery, refractive surgery, eyelid surgery or ocular trauma within 6 months * History of LipiFlow, iLux, Meiboflow, Intense Pulsed Light (IPL) or low level light therapy (LLLT) within the last 12 months * Use of photosensitizing medications * Pregnant and/or lactating females * Pigmented lesions, tattoos, or skin cancer in the periocular region

What they're measuring

Meibum protein composition

Timeframe: 3 weeks

Trial details

NCT IDNCT05859295

SponsorUniversity of Houston

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-11-11

View on ClinicalTrials.gov More Meibomian Gland Dysfunction trials